Electra Therapeutics Broadens Ipsoprubart Program With New T Cell Cancer Trial

Electra Therapeutics launched a new Phase 1 trial of its lead candidate ipsoprubart (ELA026) in relapsed or refractory T cell malignancies, marking a strategic expansion beyond its ongoing pivotal study in secondary hemophagocytic lymphohistiocytosis. The move positions the company to address rare, aggressive lymphomas and leukemias where more than 13,000 patients in the U.S. each year face limited durable treatment options.

Ipsoprubart is a first-in-class SIRP-targeting monoclonal antibody designed to deplete pathological T cells and myeloid cells through direct tumor cell elimination and modulation of the tumor microenvironment. The open-label Phase 1 study will enroll adults for up to six four-week treatment cycles, with an initial dose-finding stage followed by expansion cohorts to further evaluate safety, response rate, duration of response, and disease control.

Electra’s decision is supported by earlier Phase 1b data in lymphoma-associated sHLH, where eight patients, including six with T cell malignancies, achieved a 100% objective response rate and an 88% complete response rate, including a durable complete response in a heavily pretreated patient. These data have reportedly generated strong investigator interest and underpin Electra’s broader SIRP-focused pipeline, which also includes its second candidate, ELA822, for immunology and inflammation indications.

The expansion into T cell malignancies suggests Electra is pursuing a broader oncology strategy that could increase the future addressable market for ipsoprubart and diversify risk beyond a single rare disease indication. While the program remains in an early and high-risk stage, positive safety and efficacy signals could strengthen the company’s competitive position in hematologic cancers and potentially support future partnerships or financing.

At the same time, timelines, regulatory pathways, and ultimate commercialization prospects remain uncertain, consistent with the challenges typical of early-stage oncology development. Overall, the week underscores Electra Therapeutics’ efforts to leverage its SIRP-targeting platform across multiple indications while carefully advancing its lead asset through early clinical testing.